

Participate in Research: A randomized placebo-controlled trial of ARBaclofen vs. placebo in the treatment of children and adolescents with ASD



**Principal Investigator:
Dr. Muhammad Ayub**

**Queen's University:
Psychiatry Department**



CONTACT INFORMATION:

For more information,
contact Jennifer
Lalonde at
613-548-4417 ext. 1111

Date Posted:

Version Date:
[V.2] 30Oct2018

The **Province of Ontario Neurodevelopmental Disorders (POND) Network** is researching genes, the brain, and behaviour to find potential treatments in autism spectrum disorder (ASD).

What is this study about?

We are currently investigating a study drug called arbaclofen to improve social functioning in children and teens with Autism!

Who can participate?

We are looking for:

- Children and teens between **5 and 17 years** old
- Diagnosed with an autism spectrum disorder (ASD)
- Able to tolerate bloodwork

What's involved?

- This study is comparing arbaclofen against placebo for improving social & global function, and communication
- The trial is 18 weeks long
- All participants who complete the study are eligible for the open-label phase (where all participants receive the study drug)
- There are 9 study visits
- Study procedures include height and weight, bloodwork, EEG, and questionnaires

Potential Benefits?

- Arbaclofen may help improve social functioning
- This research will help other children and families with ASD

Potential Risks?

- The most common side effects are sedation (tiredness) and upset stomach

Participants will receive a gift card at each visit to thank them for their time.

